Thailand Diabetes Care Drugs Market Size

Thailand Diabetes Care Drugs Market Analysis

The Thailand Diabetes Care Drugs Market size is estimated at USD 152.23 million in 2024, and is expected to reach USD 173.23 million by 2029, growing at a CAGR of 3.80% during the forecast period (2024-2029).

The healthcare system was significantly disturbed and pressured during each phase of rapid COVID-19 infection. Several countries, notably the Thai government, introduced home isolation or a home quarantine program to avert healthcare collapse and to ameliorate inadequate healthcare resources. Between July 2021 and October 2021, COVID-19 illness cases in Thailand increased to around 20,000-25,000 cases per day, posing difficulty in treating COVID-19 infection in hospitals. Previous research revealed the viability of a COVID-19 home monitoring program employing telemedicine to reduce the gap in treatment during a healthcare worker shortage in multiple countries. These programs monitored the intensity of symptoms and informed patients to seek additional treatment if necessary. 

During COVID-19, there was a shortage of hospital capacity, and a home isolation system was set up. Thailand's government introduced diabetes self-management education and support (DSMES, glycemic management via telemedicine, and outcomes in home-isolated patients with COVID-19 infection. In August 2022, The National Research Council of Thailand (NRCT) introduced a breathalyzer prototype that can detect those infected with COVID-19 with 97% accuracy.

In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.